- Home
- DT vs BBIO Comparison
DT vs BBIO Comparison
Compare DT & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | BBIO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 12.7B |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DT | BBIO |
|---|---|---|
| Price | $41.14 | $69.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 25 |
| Target Price | $51.77 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 6.3M | 3.0M |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $2,018,387,000.00 | $502,076,000.00 |
| Revenue This Year | $21.74 | $89.45 |
| Revenue Next Year | $14.85 | $73.78 |
| P/E Ratio | $81.15 | ★ N/A |
| Revenue Growth | 18.82 | ★ 126.26 |
| 52 Week Low | $31.64 | $31.77 |
| 52 Week High | $57.55 | $84.94 |
Technical Indicators
Market Signals| Indicator | DT | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 49.29 |
| Support Level | $32.88 | $61.95 |
| Resistance Level | $46.56 | $69.22 |
| Average True Range (ATR) | 1.67 | 3.01 |
| MACD | 0.20 | 0.30 |
| Stochastic Oscillator | 97.44 | 68.06 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.